ADVISORY/NeoPharm to Unveil Four Abstracts at the 95th Annual Meeting of the American Association for Cancer Research.Business Editors/Health/Medical Writers ADVISORY... BIOWIRE2K --(BUSINESS WIRE) NeoPharm, Inc. (Nasdaq/NM:NEOL): Who/What: NeoPharm, Inc. (Nasdaq/NM:NEOL) to unveil four (4) abstracts at the 95th American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ) Annual Meeting (March 27-31, 2004) Why: NeoLipid(TM) drug product candidates - New data will be presented on NeoLipid(TM) liposomes-based drug products and NeoPhectin(TM) family of transfection reagents Where: Orange County Convention Center The Orange County Convention Center (OCCC) is the primary public convention center in Central Florida. The large complex is located on International Drive, a major tourist area in Orlando, Florida. , Orlando, Florida When: The following studies will be presented as scientific posters at AACR Sunday, March 28th beginning at 8:00 am in the session of Experimental and Molecular Therapeutics 6: -- Abstract# 637 Enhanced Therapeutic Efficacy of Liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. Entrapped raf Antisense Oligonucleotide in Combination with Taxotere(R) in Xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, Model of Human Prostate Cancer. -- Abstract# 638 Enhanced Therapeutic Efficacy of a novel liposome-based formulation of c-raf AON in combination with Taxol(R) against human ovarian tumor model in SCID SCID severe combined immunodeficiency (disease); see under immunodeficiency. SCID abbr. severe combined immunodeficiency SCID severe combined immunodeficiency disease. mice. -- Abstract# 643 Entrapment entrapment, in law, the instigation of a crime in the attempt to obtain cause for a criminal prosecution. Situations in which a government operative merely provides the occasion for the commission of a criminal act (e.g. of doxorubicin or mitoxantrone into liposomal paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); for combination therapy. The following study will be presented Tuesday, March 30th beginning at 1:00 pm in the session of Experimental and Molecular Therapeutics 43: -- Abstract# 4606 NeoPhectin(TM), Novel Cationic cationic having qualities dependent on having free cations available. cationic detergents are wetting agents that disrupt or damage cell membranes, denature proteins and inactivate enzymes. Cardiolipin Liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. for Safe and Enhanced Transfection of Cells About NeoPharm, Inc. NeoPharm, Inc., based in Lake Forest, Illinois Lake Forest is a city in Lake County, Illinois, United States. The population was 20,059 at the 2000 census. The city is south of Waukegan, Illinois, on the shore of Lake Michigan, and is a part of the Chicago metropolitan area and the North Shore. , is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a broad portfolio of cancer compounds in various stages of development. In 2003, NeoPharm, Inc. was recognized as "Champion of the AACR" for its ongoing support of AACR programs. Additional information can be obtained by visiting NeoPharm's Website at: www.neophrm.com. Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials involving the Company's drug product candidates, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug and non-drug compounds, including, but not limited to uncertainty regarding the availability of third party production capacity, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products directly or through independent distributors, the uncertainty of patent protection for the Company's intellectual property or trade secrets and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion